What's The Next Growth Driver For Johnson & Johnson?
5d 1m 3m 1y 5y 10y
There are no Focus articles on MVRBF.
There are no Transcripts on MVRBF.
There are no News articles on MVRBF.
MVRBF vs. ETF Alternatives
Nov. 24, 2013, 2:59 AM
- The FDA has approved Johnson & Johnson's (JNJ) and Medivir's (MVRBF) simeprevir pill for the treatment of chronic hepatitis C.
- The agency authorized that the drug, to be called Olysio, be used with other medicines.
- Olysio is part of a new wave of Hepatitis C treatments to be developed, with Gilead (GILD) and Bristol-Myers Squibb (BMY) among other companies that are working on such drugs.
- Analysts have forecast that Olysio will generate sales of almost $450M in 2016. (PR)
Mar. 4, 2013, 3:15 PMA combination of Gilead's (GILD +0.6%) Sofosbuvir and Simeprevir, a drug being jointly developed by Medivir (MVRBF.PK) and Johnson & Johnson's (JNJ) Janssen unit, eliminates hepatitis C in all 80 patients in a Phase IIa study. The patients had failed to respond to other treatments. "We went for the most difficult to cure, with the idea if we could show good efficacy there, it could be assumed the regimen could be efficacious in other patient populations," says Gaston Picchio of Medivir partner J&J (JNJ +0.5%). (PR) | Mar. 4, 2013, 3:15 PM | 2 Comments
Other TSLA news & PR